Clinical Trial Update: Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rivaroxaban for treatment of deep vein thrombosis in patients using a strong CYP3A4 inducer; results were completed and posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Venous Thrombosis

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thrombosis, Deep Vein Thrombosis | Phase 2 | Status: COMPLETED | Results posted: 2014-06-13